Blackstone Inc
ALNY icon

Blackstone Inc’s Alnylam Pharmaceuticals ALNY Stock Holding History

Blackstone Inc’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
4,611
-4,164
-47% -$1.26M ﹤0.01% 220
2026
Q1 		$2.9M Buy
+8,775
New +$2.99M 0.01% 170
2022
Q2 		– Sell
-517,391
Closed -$84.5M – 249
2022
Q1 		$84.5M Hold
517,391
– – 0.21% 46
2021
Q4 		$87.7M Hold
517,391
– – 0.22% 58
2021
Q3 		$97.7M Hold
517,391
– – 0.22% 57
2021
Q2 		$87.7M Sell
517,391
-120,436
-19% -$17.6M 0.2% 55
2021
Q1 		$90.1M Hold
637,827
– – 0.18% 53
2020
Q4 		$82.9M Sell
637,827
-178,245
-22% -$23.8M 0.29% 40
2020
Q3 		$119M Sell
816,072
-108,609
-12% -$15.4M 0.46% 30
2020
Q2 		$137M Buy
+924,681
New +$125M 0.58% 26

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blackstone Inc's ALNY Position: Q2 2026 in Review

Blackstone Inc reduced its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q2 2026, selling an estimated $1.26M and leaving 4,611 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Blackstone Inc first reported a position in ALNY in Q2 2020 and has held it in 10 quarters since. The position peaked at $137M in Q2 2020. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Blackstone Inc held 4,611 shares of Alnylam Pharmaceuticals worth $1.39M as of Q2 2026.
  • Blackstone Inc sold 4,164 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.26M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #220 holding.
  • Blackstone Inc first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
  • Blackstone Inc's Alnylam Pharmaceuticals position peaked at $137M in Q2 2020.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.